CFD-d on keerulised instrumendid, millega kaasneb võimenduse tõttu suur risk kiiresti raha kaotada. 84% jaeinvestoritest kaotab selle pakkuja juures CFD-dega kaubeldes raha. Mõelge järele, kas mõistate CFD-de toimimise põhimõtet ja kas saate endale lubada riski rahast ilma jääda.

Ost-müük Pieris Pharmaceuticals, Inc. - PIRS CFD

0.72
8.86%
  • Kokkuvõte
  • Ajaloolised andmed
  • Sündmused
  • Tuluaruanne
  • Bilanss
  • Rahavood
  • Omand
Kauplemistingimused
Hinnavahe 0.06
Pika positsiooni ööpäeva tasu

Long position overnight fee


Margin. Your investment $1,000.00
Üleöö tasu -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Mine platvormile
-0.025457%
Lühikese positsiooni ööpäeva tasu

Short position overnight fee


Margin. Your investment $1,000.00
Üleöö tasu 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Mine platvormile
0.003235%
Ööpäeva tasu aeg 21:00 (UTC)
Min kauplemise kogus 1
Valuuta USD
Tagatis 20%
Aktsiabörs United States of America
Kauplemise vahendustasu 0%

*Information provided by Capital.com

Pieris Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

Võtmestatistika
Eelmine sulgemine* 0.79
Avatud* 0.8
Aastane muutus* -52.1%
Päeva ulatus* 0.72 - 0.85
52 nädala ulatus 0.72-2.12
Keskmine maht (10 päeva) 743.53K
Keskmine maht (3 kuud) 13.81M
Turukapitalisatsioon 61.51M
P/E suhtarv -100.00K
Ringluses olevad aktsiad 82.02M
Tulu 16.85M
EPS -0.56
Dividendid (% kasumist) N/A
Beeta 1.08
Järgmine tuluaruande kuupäev Aug 2, 2023

Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Sulgemishind Change (%) Avamishind High Low
May 26, 2023 0.72 -0.08 -10.00% 0.80 0.85 0.72
May 25, 2023 0.79 -0.04 -4.82% 0.83 0.84 0.79
May 24, 2023 0.85 -0.02 -2.30% 0.87 0.88 0.84
May 23, 2023 0.89 -0.03 -3.26% 0.92 0.92 0.86
May 22, 2023 0.84 0.02 2.44% 0.82 0.84 0.77
May 19, 2023 0.79 -0.07 -8.14% 0.86 0.87 0.78
May 18, 2023 0.83 0.02 2.47% 0.81 0.94 0.79
May 17, 2023 0.76 0.00 0.00% 0.76 0.79 0.74
May 16, 2023 0.77 -0.05 -6.10% 0.82 0.82 0.77
May 15, 2023 0.83 0.00 0.00% 0.83 0.85 0.78
May 12, 2023 0.84 -0.08 -8.70% 0.92 0.92 0.82
May 11, 2023 0.93 0.12 14.81% 0.81 0.96 0.76
May 10, 2023 0.84 0.06 7.69% 0.78 0.84 0.75
May 9, 2023 0.82 0.02 2.50% 0.80 0.82 0.73
May 8, 2023 0.80 -0.02 -2.44% 0.82 0.84 0.79
May 5, 2023 0.83 0.05 6.41% 0.78 0.85 0.78
May 4, 2023 0.77 -0.03 -3.75% 0.80 0.84 0.74
May 3, 2023 0.79 0.03 3.95% 0.76 0.80 0.72
May 2, 2023 0.74 0.03 4.23% 0.71 0.74 0.70
May 1, 2023 0.73 0.00 0.00% 0.73 0.74 0.70

Pieris Pharmaceuticals, Inc. Events

Kellaaeg (UTC) (UTC) Riik Sündmus
Wednesday, June 21, 2023

Kellaaeg (UTC) (UTC)

12:00

Riik

US

Sündmus

Pieris Pharmaceuticals Inc Annual Shareholders Meeting
Pieris Pharmaceuticals Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, June 22, 2023

Kellaaeg (UTC) (UTC)

12:00

Riik

US

Sündmus

Pieris Pharmaceuticals Inc Annual Shareholders Meeting
Pieris Pharmaceuticals Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, August 2, 2023

Kellaaeg (UTC) (UTC)

12:30

Riik

US

Sündmus

Q2 2023 Pieris Pharmaceuticals Inc Earnings Release
Q2 2023 Pieris Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Tuesday, October 31, 2023

Kellaaeg (UTC) (UTC)

12:30

Riik

US

Sündmus

Q3 2023 Pieris Pharmaceuticals Inc Earnings Release
Q3 2023 Pieris Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Vaadake kõiki sündmusi
  • Aastas
  • Kvartalis
2022 2021 2020 2019 2018
Kogutulu 25.902 31.418 29.323 46.279 29.101
Tulu 25.902 31.418 29.323 46.279 29.101
Kogu tegevuskulu 61.203 79.564 63.244 73.436 59.932
Müük/Üldine/admin kulud, kokku 16.394 16.593 16.713 18.44 18.442
Uuringud ja arendus 52.982 66.656 46.531 54.996 41.49
Tulud majandustegevusest -35.301 -48.146 -33.921 -27.157 -30.831
Intressitulud (kulu), muud tulud, neto 0.721 0.004 0.511 1.714 1.962
Muud, neto 1.303 2.404 -3.656 -0.026 1.803
Netotulu enne makse -33.277 -45.738 -37.066 -25.469 -27.066
Netotulu pärast makse -33.277 -45.738 -37.23 -25.469 -26.754
Netotulu enne erikulusid -33.277 -45.738 -37.23 -25.469 -26.754
Netotulu -33.277 -45.738 -37.23 -25.469 -26.754
Total Adjustments to Net Income -2.83
Arvestatav tulu, v a erikulud -33.277 -45.738 -37.23 -28.299 -26.754
Arvestatav tulu, koos erikuludega -33.277 -45.738 -37.23 -28.299 -26.754
Jaotamisele kuuluv netotulu -33.277 -45.738 -37.23 -28.299 -26.754
Keskmine jaotamisele kuuluv aktsia kohta 74.172 64.547 54.481 50.625 53.081
Jaotatav EPS, v a erakorralised kulud -0.44865 -0.7086 -0.68336 -0.55899 -0.50402
Jaotamisele kuuluv normaal-EPS -0.55884 -0.76569 -0.68336 -0.55899 -0.50402
Erakorralised kulud kokku
Ootamatud kulutused (tulu) -8.173 -3.685
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Kogutulu 1.936 5.846 5.37 3.698 10.988
Tulu 1.936 5.846 5.37 3.698 10.988
Kogu tegevuskulu 15.419 13.974 16.07 14.844 16.315
Müük/Üldine/admin kulud, kokku 4.023 3.985 3.949 4.081 4.379
Uuringud ja arendus 13.424 13.38 13.589 11.947 14.066
Tulud majandustegevusest -13.483 -8.128 -10.7 -11.146 -5.327
Intressitulud (kulu), muud tulud, neto 0.357 0.351 0.241 0.132 -0.003
Muud, neto -0.057 -0.325 0.723 0.676 0.229
Netotulu enne makse -13.183 -8.102 -9.736 -10.338 -5.101
Netotulu pärast makse -13.183 -8.102 -9.736 -10.338 -5.101
Netotulu enne erikulusid -13.183 -8.102 -9.736 -10.338 -5.101
Netotulu -13.183 -8.102 -9.736 -10.338 -5.101
Arvestatav tulu, v a erikulud -13.183 -8.102 -9.736 -10.338 -5.101
Arvestatav tulu, koos erikuludega -13.183 -8.102 -9.736 -10.338 -5.101
Jaotamisele kuuluv netotulu -13.183 -8.102 -9.736 -10.338 -5.101
Keskmine jaotamisele kuuluv aktsia kohta 74.519 74.448 74.397 74.125 73.711
Jaotatav EPS, v a erakorralised kulud -0.17691 -0.10883 -0.13087 -0.13947 -0.0692
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Jaotamisele kuuluv normaal-EPS -0.20412 -0.15438 -0.1506 -0.15544 -0.0981
Ootamatud kulutused (tulu) -2.028 -3.391 -1.468 -1.184 -2.13
  • Aastas
  • Kvartalis
2022 2021 2020 2019 2018
Käibevarad kokku 73.424 127.625 75.721 115.013 135.382
Raha ja lühiajalised investeeringud 59.169 117.764 70.436 104.154 128.107
Raha ja ekvivalendid 38.635 117.764 70.436 62.26 74.867
Laekumata arved, neto 5.81 3.313 1.706 6.787 2.701
Accounts Receivable - Trade, Net 5.81 3.313 1.706 6.787 2.701
Prepaid Expenses 8.445 6.548 3.579 4.072 4.574
Total Assets 95.49 153.56 105.01 141.097 141.341
Property/Plant/Equipment, Total - Net 20.697 23.031 25.98 22.938 5.049
Property/Plant/Equipment, Total - Gross 30.344 30.748 31.795 26.505 8.415
Accumulated Depreciation, Total -9.647 -7.717 -5.815 -3.567 -3.366
Other Long Term Assets, Total 1.369 2.904 3.309 3.146 0.91
Total Current Liabilities 36.583 50.561 22.145 27.003 48.076
Accounts Payable 4.154 8.609 1.787 5.803 3.35
Accrued Expenses 11.122 14.833 7.496 9.486 8.169
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 21.307 27.119 12.862 11.714 36.557
Total Liabilities 67.561 102.805 73.983 89.745 101.406
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 30.978 52.244 51.838 62.742 53.33
Total Equity 27.929 50.755 31.027 51.352 39.935
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.074 0.072 0.056 0.055 0.054
Additional Paid-In Capital 318.53 306.998 242.672 227.468 189.929
Retained Earnings (Accumulated Deficit) -290.421 -257.144 -211.406 -174.176 -147.066
Other Equity, Total -0.254 0.829 -0.295 -1.995 -2.982
Total Liabilities & Shareholders’ Equity 95.49 153.56 105.01 141.097 141.341
Total Common Shares Outstanding 74.5191 72.2227 56.0028 55.2124 54.1512
Lühiajalised investeeringud 20.534 0 41.894 53.24
Long Term Investments 0
Total Preferred Shares Outstanding 0.00762 0.00762 0.01443 0.01143
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Käibevarad kokku 60.505 73.424 78.56 90.904 111.749
Raha ja lühiajalised investeeringud 48.379 59.169 69.823 80.936 100.268
Raha ja ekvivalendid 39.742 38.635 48.423 54.257 83.737
Laekumata arved, neto 1.055 5.81 0.829 1.264 1.644
Accounts Receivable - Trade, Net 1.055 5.81 0.829 1.264 1.644
Prepaid Expenses 11.071 8.445 7.908 8.704 9.837
Total Assets 82.258 95.49 99.163 114.309 137.115
Property/Plant/Equipment, Total - Net 20.502 20.697 19.296 21.047 22.693
Property/Plant/Equipment, Total - Gross 30.476 30.344 27.615 29.292 30.87
Accumulated Depreciation, Total -9.974 -9.647 -8.319 -8.245 -8.177
Other Long Term Assets, Total 1.251 1.369 1.307 2.358 2.673
Total Current Liabilities 42.875 36.583 33.521 35.546 39.484
Accounts Payable 5.833 4.154 3.641 1.898 4.496
Accrued Expenses 9.764 11.122 10.801 10.175 11.858
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 27.278 21.307 19.079 23.473 23.13
Total Liabilities 66.8 67.561 63.396 69.944 83.665
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 23.925 30.978 29.875 34.398 44.181
Total Equity 15.458 27.929 35.767 44.365 53.45
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.074 0.074 0.074 0.074 0.074
Additional Paid-In Capital 319.414 318.53 317.488 316.249 314.668
Retained Earnings (Accumulated Deficit) -303.604 -290.421 -282.319 -272.583 -262.245
Other Equity, Total -0.426 -0.254 0.524 0.625 0.953
Total Liabilities & Shareholders’ Equity 82.258 95.49 99.163 114.309 137.115
Total Common Shares Outstanding 74.5191 74.5191 74.4062 74.2576 74.0979
Total Preferred Shares Outstanding 0.00762 0.00762 0.00762 0.00762 0.00762
Lühiajalised investeeringud 8.637 20.534 21.4 26.679 16.531
  • Aastas
  • Kvartalis
2022 2021 2020 2019 2018
Netotulu/algväärtus -33.277 -45.738 -37.23 -25.469 -26.754
Raha majandustegevusest -59.932 -7.66 -45.896 -52.467 -1.066
Raha majandustegevusest 2.77 2.459 2.311 0.632 0.57
Mittelikviidsed varad 3.945 5.094 5.236 4.491 3.389
Cash Taxes Paid 0 0.908
Makstud intressid
Muutused tööjõus -33.37 30.525 -16.377 -32.121 21.893
Tulu investeeringutelt -21.236 -0.949 39.212 9.838 -8.875
Kapitalikulutused -1.041 -0.949 -2.726 -2.462 -1.698
Muud rahavood investeeringutelt, kokku -20.195 0 41.938 12.3 -7.177
Rahavood investeeringutelt 7.214 59.127 10.115 32.166 48.511
Aktsiate emiteerimine (tagasiost), neto 7.017 58.962 9.915 31.797 48.511
Muutused valuutakursside kõikumisest -5.175 -3.19 4.745 -2.144 -1.581
Rahaline kogumuutus -79.129 47.328 8.176 -12.607 36.989
Deferred Taxes 0 0.164 0 -0.164
Rahavoogudesse investeerimine 0.197 0.165 0.2 0.369
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -13.183 -33.277 -25.175 -15.439 -5.101
Cash From Operating Activities -10.996 -59.932 -46.999 -38.221 -22.643
Cash From Operating Activities 0.605 2.77 2.195 1.428 0.845
Non-Cash Items 0.975 3.945 3.37 2.728 1.264
Changes in Working Capital 0.607 -33.37 -27.389 -26.938 -19.651
Cash From Investing Activities 11.903 -21.236 -22.343 -27.813 -16.948
Capital Expenditures -0.048 -1.041 -1.052 -1.018 -0.389
Other Investing Cash Flow Items, Total 11.951 -20.195 -21.291 -26.795 -16.559
Cash From Financing Activities 0 7.214 7.121 6.839 6.558
Issuance (Retirement) of Stock, Net 0 7.017 7.017 6.735 6.558
Foreign Exchange Effects 0.2 -5.175 -7.12 -4.312 -0.994
Net Change in Cash 1.107 -79.129 -69.341 -63.507 -34.027
Financing Cash Flow Items 0.197 0.104 0.104
Deferred Taxes
Investori nimi Investori liik Ringluse protsent Hoitud osakud Muutus osakutes Hoidmise kuupäev Hinnang käibele
BVF Partners L.P. Hedge Fund 25.1281 20609863 15529543 2023-05-11 LOW
Lynx1 Capital Advisors LLC Investment Advisor 8.6172 7067718 1439133 2023-03-31
Aquilo Capital Management, LLC Investment Advisor/Hedge Fund 5.551 4552876 0 2023-03-31
Soleus Capital Management, L.P. Hedge Fund 5.0413 4134868 134868 2023-03-31 HIGH
Seagen Inc Corporation 4.5187 3706174 0 2022-12-31
AstraZeneca PLC Corporation 4.37 3584230 0 2022-12-31 LOW
Pontifax Ltd. Venture Capital 4.3544 3571428 0 2021-12-31 LOW
Marshall Wace LLP Investment Advisor/Hedge Fund 2.7632 2266350 -125686 2023-03-31 HIGH
Citadel Advisors LLC Hedge Fund 2.4383 1999907 -46254 2023-03-31 HIGH
Medical Strategy GmbH Investment Advisor 1.9744 1619387 52729 2023-01-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.4366 1178283 -114163 2023-03-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.2626 1035540 -29441 2023-03-31 LOW
Platinum Asset Management Investment Advisor/Hedge Fund 1.1888 975012 -245786 2023-03-31 LOW
Acadian Asset Management LLC Investment Advisor/Hedge Fund 0.769 630690 -251144 2023-03-31 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7681 629965 0 2023-03-31 LOW
BMO Capital Markets (US) Research Firm 0.5873 481727 481727 2022-12-31 MED
Walleye Capital LLC Hedge Fund 0.5839 478935 478935 2023-03-31 HIGH
Renaissance Technologies LLC Hedge Fund 0.4699 385391 -301600 2023-03-31 HIGH
Cutter & Company, Inc. Investment Advisor 0.4602 377479 -1000 2023-03-31 LOW
Candriam Luxembourg S.A. Investment Advisor 0.429 351834 -245000 2023-03-31 HIGH

Miks valida Capital.com? Meie numbrid räägivad iseenda eest.

Capital.com Group

530K+

Kauplejad

87K+

Igakuiste aktiivsete klientide arv

$46M+

Igakuine investeerimise maht

$31M+

Igakuiselt välja võetud

Kauplemiskalkulaator

Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).

Kauplemise vahendustasu
0
  • 1:1
Finantsvõimendus
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind

Close

Lühike Pikk

Pieris Pharmaceuticals, Inc. Company profile

Ettevõttest Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc. on kliinilise faasi biotehnoloogiaettevõte, mis avastab ja arendab antikaliinil põhinevaid ravimeid, mis on suunatud valideeritud haigusradadele. Ettevõtte juhtiv hingamisteede antikaliinil põhinev ravimikandidaat PRS-060/AZD1402, mis antagoniseerib IL-4R alfa, inhibeerides seeläbi IL-4 ja IL-13, kaks tsütokiini, väikesed valgud, mis vahendavad rakkude vahelist signalisatsiooni inimkehas ja on teadaolevalt põletikukaskadi vahendajad, mis põhjustavad astma ja teiste põletikuliste haiguste patogeneesi. IO Anticalinil põhinev juhtiv ravimikandidaat, cinrebafusp alfa, mis on kavandatud immuunretseptori 4-1BB ja kasvaja sihtmärgi HER2 vastu. Cinrebafusp alfa on HER2-le suunatud antikeha variandi geneetiline fusioon 4-1BB-le spetsiifilise Anticalin-valguga.

Industry: Bio Therapeutic Drugs

225 Franklin Street
26Th Floor
BOSTON
MASSACHUSETTS 02110
US

Tuluaruanne

  • Annual
  • Quarterly

Teised on vaadanud veel

BTC/USD

27,949.75 Price
+1.310% 1D Chg, %
Pika positsiooni ööpäeva tasu -0.0616%
Lühikese positsiooni ööpäeva tasu 0.0137%
Ööpäeva tasu aeg 21:00 (UTC)
Hinnavahe 60.00

XRP/USD

0.48 Price
+0.540% 1D Chg, %
Pika positsiooni ööpäeva tasu -0.0753%
Lühikese positsiooni ööpäeva tasu 0.0069%
Ööpäeva tasu aeg 21:00 (UTC)
Hinnavahe 0.00370

Oil - Crude

72.45 Price
-0.670% 1D Chg, %
Pika positsiooni ööpäeva tasu -0.0154%
Lühikese positsiooni ööpäeva tasu -0.0065%
Ööpäeva tasu aeg 21:00 (UTC)
Hinnavahe 0.03

US100

14,341.30 Price
+0.090% 1D Chg, %
Pika positsiooni ööpäeva tasu -0.0255%
Lühikese positsiooni ööpäeva tasu 0.0032%
Ööpäeva tasu aeg 21:00 (UTC)
Hinnavahe 1.8

Kas otsite jätkuvalt vahendajat, keda saab usaldada?

Ühinege 530,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com

1. Looge ja kinnitage oma konto 2. Tee sissemakse 3. Alusta kauplemist